HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Fuels ‘2.0’ Relaunch With Survey: 40% Of US Consumers Have Some Sort Of Second Job

Executive Summary

Survey it commissioned shows 40% of US consumers turning to “side hustles” such as selling products for MLMs. Firm also launched 106 SKUs during the January-March period and has hired former Fiat Chrysler Automobiles exec as investors relations VP.

You may also be interested in...



US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.

Herbalife Relaunches To ‘2.0’ With 'Unified, Global Platform' After Sales Fall 10.3% In 2022

Direct seller announces relaunch after year-long sales slump blamed on macroeconomic inflationary pressures. No full-year guidance due to rapidly shifting macroeconomic environment and increased market volatility.

Twice Retired Herbalife CEO Johnson Returns To Helm For $1 Salary Plus Stock Incentives

Michael Johnson previously was CEO from 2003 to 2017 and from 2019 to early 2020, as well as chairman from 2007 to early 2020. Direct seller granted him an equity-based long-term incentive plan in stock appreciation rights and restricted stock units.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel